RESUMO
BACKGROUND: Post-prandial hyperglycemia (PPHG) remains a complex aspect in the management of type 2 diabetes mellitus (T2DM) in the Indian population due to uncertainty in the optimal utilization of alpha-glucosidase inhibitors (AGIs) either as standalone therapy or in combination, whether initiated initially or as a sequential therapy. METHODS: This was a post-approval, observational, multicentric clinical study conducted at 50 centers according to principles of the International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use Guideline for Good Clinical Practice (ICH-GCP) and Declaration of Helsinki and local ethics approval. Descriptive and analytical statistics were applied for conclusion and categorical variables using SPSS version 29.0.1.0 (171) (Armonk, NY: IBM Corp.). RESULTS: Protocol analyses of 515 cases revealed baseline demographics as follows: age 57.35±10.04 years, weight 72.86±10.92 kg, and BMI 28.33±6.07 kg/m2. Comorbidities included hypertension (N=169, 32.82%), thyroid disorders (N=99, 19.22%), and heart failure (N=92, 17.86%). Concomitant oral antidiabetics (OADs) prescribed as DPP4i (9.50%), SGLT2i (19.20%), and DPP4i+SGLT2i (7.20%). Study drug reduced glycosylated hemoglobin (HbA1c) by 13.77% (1.25% mean change, p<0.01), fasting blood glucose (FBG) by 23.69% (44.61 mg/dL mean change, p<0.01), post-prandial blood glucose (PPBG) by 24.57% (70.46 mg/dL mean change, p<0.01), and body weight by 4.43% (3.21 kg mean change, p<0.01) over 12 weeks. A total of 161 patients accomplished targeted PPBG of <180 mg/dL (119.13 mg/dL mean change, p<0.01). Regression analysis considering PPBG and HbA1c ≤7.5% showed a weak correlation between them (R-value=0.13, R-squared value=0.02), whereas between PPBG and HbA1c ≤9% yielded moderate positive correlation (R-value=0.53, R-squared value=0.28). There were no adverse events reported or analyzed during the observation period. CONCLUSION: Voglibose fixed-dose combination (FDC) demonstrates significant effectiveness at the initial dosage when started early in the management of T2DM and high PPBG levels. Moreover, it exhibits good tolerability, thereby contributing to higher compliance among Indian patients who consume a high-carbohydrate diet.
RESUMO
Ionanofluids (INFs), nanoparticles dispersed into a base fluid, e.g. an ionic liquid, are a novel class of alternative heat transfer fluids. Addition of nanoparticles to a base ionic liquid is the prime reason for an enhancement in the thermophysical properties of ionanofluids. However, due to very limited research on ionanofluids, further studies are required to understand changes in the isobaric heat capacity of ionanofluids as a function of size of cations of the base ionic liquid structure and concentration of nanoparticles. Herein, isobaric heat capacity was measured as a function of temperature for the prepared ionanofluid samples from a series of imidazolium ionic liquids and multi walled carbon nanotubes (MWCNTs). Moreover, the influence of the size of cations on the isobaric heat capacity enhancement mechanism and the stability of ionanofluid samples was studied. Furthermore, experimental isobaric heat capacity data were assessed by a novel non-statistical data analysis method named mathematical gnostics (MG). MG marginal analysis was used to evaluate the most probable values from the measured data set. A robust linear regression along a gnostic influence function was also used to find the best fit to correlate the measured data.